Actively Recruiting
Viral Infection of HSPC Impacts Hematopoiesis
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-03-20
45
Participants Needed
1
Research Sites
70 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
CONDITIONS
Official Title
Viral Infection of HSPC Impacts Hematopoiesis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HIV-positive patients with a negative or positive viral load
- Managed at Ambroise Paré Hospital
- Patients with a bone marrow biopsy or myelogram performed as part of their care
- Healthy subjects without HIV who have had a bone marrow biopsy or myelogram for suspected hematological pathology
- Managed at Ambroise Paré Hospital
You will not qualify if you...
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hematology and interne medicine department, Ambroise Paré hospital - APHP
Boulogne-Billancourt, France, 92100
Actively Recruiting
Research Team
C
Claude CAPRON, MD, PhD
CONTACT
F
Fernando REAL, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here